RxDoctor Payments Data

Daniel Rowady, MD

Internal Medicine · Pasadena, CANPI 1578661609

Payments from drug & device makers

$1,645in general payments, 2019–2025

Across 71 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Teleflex LLC$163
  • AbbVie$57
  • Amgen$54
  • Exact Sciences$46
  • Amarin Pharma, Inc.$24
  • plus $140 from 8 others

What the payments were for

  • Food & beverage$1,645100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,645 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$230,258
Medicare patients
466
Services billed
1,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin150$198,653
EliquisApixaban84$85,516
TrulicityDulaglutide65$81,882
RybelsusSemaglutide34$65,025
XareltoRivaroxaban49$60,854
JanuviaSitagliptin Phosphate25$26,124
OzempicSemaglutide14$25,106
MounjaroTirzepatide19$22,477
FarxigaDapagliflozin Propanediol11$17,528
ElmironPentosan Polysulfate Sodium11$10,660
Rosuvastatin Calcium429$8,636
ZenpepLipase/Protease/Amylase15$8,423
PaxlovidNirmatrelvir/Ritonavir67$5,717
Valsartan173$5,698
Atorvastatin Calcium492$5,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Premarin$20$94,425166 claims
Johnson & JohnsonXarelto$16$60,85449 claims
AbbVieSynthroid$57$2,72765 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →